Mulvihill, University of Ottawa Heart Institute, 40 Ruskin Street, H-3229A Ottawa, Ontario, K1Y 4W7, Canada
A trial of omarigliptin evaluated 4202 diabetic patients without acute ischemic disease, who were followed for a median of 1.8 years, before early termination of the trial [50]
And Marinus Pharmaceuticals oral testosterone replacement therapy Kyzatrex received FDAs nod last year for a range of diseases in men that arise from deficiency or absence of endogenous testosterone
The preparation of the neutralized extract and the microplate assay were as described previously (Sivakumar and Bozzo, 2024)
But alas, those glowing claims arent yet backed by strong clinical evidence